Eurofins Scientific SE Share Price
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.98 EUR | +0.43% |
|
+2.01% | +12.15% |
| 23/07 | Eurofins Scientific SE, H1 2026 Earnings Call, Jul 23, 2026 | |
| 23/07 | Eurofins Scientific: BioPharma's slowdown raises questions on 2026 organic growth target |  |
| Market Cap | 1.21TCr 1.4TCr 1.13TCr 1.04TCr 1.96TCr 1,32800Cr 1.98TCr 13TCr 5.2TCr 66TCr 5.25TCr 5.13TCr 2,20100Cr | P/E 2026 * |
23.2x | P/E 2027 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 1.54TCr 1.78TCr 1.44TCr 1.32TCr 2.5TCr 1,69600Cr 2.53TCr 17TCr 6.64TCr 85TCr 6.7TCr 6.55TCr 2,81000Cr | EV / Sales 2026 * |
2.03x | EV / Sales 2027 * | 1.89x |
| Free-Float |
60.39% | Yield 2026 * |
1.16% | Yield 2027 * | 1.32% |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.43% | ||
| 1 week | +2.01% | ||
| Current month | +2.67% | ||
| 1 month | +1.86% | ||
| 3 months | +16.63% | ||
| 6 months | +2.91% | ||
| Current year | +12.15% |
| 1 week | 67.44 |  | 70.36 |
| 1 month | 64.56 | | 71.28 |
| Current year | 56.84 | | 74.32 |
| 1 year | 54.86 | | 74.32 |
| 3 years | 39.47 | | 74.32 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 27/02/26 | Buy | Chief Executive Officer | 1,000 | 0.0005% | ||
| 27/02/26 | Buy | Chief Executive Officer | 1,000 | 0.0005% | ||
| 27/02/26 | Buy | Chief Executive Officer | 1,000 | 0.0005% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.43% | +2.01% | +8.33% | +19.18% | 1.4TCr | |
| +0.71% | -0.63% | +3.89% | +15.59% | 4.86TCr | |
| +1.67% | +3.25% | +441.10% | +569.43% | 4.19TCr | |
| -1.79% | -1.87% | +31.47% | +6.40% | 3.89TCr | |
| +0.77% | +2.70% | +10.80% | +76.39% | 3.72TCr | |
| +2.42% | +5.72% | +12.38% | +44.79% | 3.07TCr | |
| -0.84% | +1.16% | +35.93% | +124.66% | 1.64TCr | |
| +3.70% | -0.94% | - | - | 1.61TCr | |
| -2.05% | -2.31% | +4.04% | -35.72% | 1.26TCr | |
| -0.73% | +11.95% | +74.72% | +27.95% | 1.26TCr | |
| Average | +0.43% | +0.40% | +69.18% | +94.30% | 2.69TCr | |
| Weighted average by Cap. | +0.56% | +0.40% | +88.56% | +123.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 759.17Cr 876.54Cr 707.68Cr 650.88Cr 1.23TCr 83TCr 1.24TCr 8.32TCr 3.26TCr 42TCr 3.29TCr 3.22TCr 1,38100Cr | 801.33Cr 925.21Cr 746.98Cr 687.03Cr 1.3TCr 88TCr 1.31TCr 8.78TCr 3.45TCr 44TCr 3.47TCr 3.4TCr 1,45800Cr |
| Net income | 53Cr 61Cr 50Cr 46Cr 86Cr 5.84TCr 87Cr 583.03Cr 228.83Cr 2.92TCr 230.81Cr 225.72Cr 9.68TCr | 66Cr 76Cr 62Cr 57Cr 106.99Cr 7.26TCr 108.19Cr 724.11Cr 284.2Cr 3.63TCr 286.65Cr 280.33Cr 12TCr |
| Net Debt | 334.87Cr 386.64Cr 312.16Cr 287.11Cr 542.01Cr 37TCr 548.07Cr 3.67TCr 1.44TCr 18TCr 1.45TCr 1.42TCr 61TCr | 301.26Cr 347.84Cr 280.83Cr 258.29Cr 487.61Cr 33TCr 493.06Cr 3.3TCr 1.3TCr 17TCr 1.31TCr 1.28TCr 55TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | €69.98 | +0.43% | 75,772 |
| 05/26/05 | €69.68 | +1.25% | 1,37,595 |
| 04/26/04 | €68.82 | +1.59% | 2,00,977 |
| 03/26/03 | €67.74 | -0.62% | 2,14,239 |
| 31/26/31 | €68.16 | -0.64% | 1,83,678 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
